TACE with immunotherapy drugs for advanced liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of TACE (a procedure that blocks blood supply to the tumor) plus three immunotherapy drugs (sintilimab, bevacizumab, ipilimumab) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this combination works better than TACE alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced liver cancer (HCC) that cannot be removed by surgery or has spread to other parts of the body.
- You must be between 18 and 75 years old.
- You must be well enough to be up and about (ECOG score 0-1).
- Your liver function must be fairly good (Child-Pugh score 7 or less).
- You must have at least one tumor that can be measured on a scan.
- You cannot have had prior treatment with TACE, other artery treatments, or systemic therapy for liver cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people with advanced liver cancer (HCC) that has spread outside the liver. It tests whether combining a TACE procedure with immunotherapy and anti-angiogenesis drugs can improve outcomes. You must not have had prior systemic therapy and must have received TACE in a specific time window around starting these drugs.
This study tests a combination of a liver-directed treatment (TACE) with two immunotherapy drugs and bevacizumab for patients with liver cancer that cannot be surgically removed but has not spread outside the liver. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests a new immunotherapy drug (GKL-006) combined with a standard treatment called TACE (which blocks blood flow to the tumor) for people with liver cancer that cannot be removed by surgery. The goal is to see if adding this drug helps shrink tumors more than TACE alone.
This trial tests a combination of two treatments for advanced liver cancer: TACE (a procedure that blocks the blood supply to the tumor) and an anti-PD-1 antibody (a type of immunotherapy that helps your immune system fight cancer). The goal is to see if this combination works better than either treatment alone and to understand how it affects the immune system around the tumor.
This trial is for people with advanced liver cancer (HCC) that has spread outside the liver or into major blood vessels. It tests combining a procedure called TACE with immunotherapy (PD-1/PD-L1 inhibitors) and targeted drugs to see how well they work together.
This trial tests whether combining TACE (a procedure that blocks blood supply to the tumor) with three medicines (SHR-8068, adebrelimab, and bevacizumab) works better than TACE alone for people with incurable liver cancer that can't be removed surgically.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.